美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Inhibrx Biosciences, Inc.

15.86

0.0000

成交量：- -

成交額：1,097.66萬

市值：2.26億

市盈率：- -

高：15.86

開：15.86

低：15.86

收：15.86

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Inhibrx Biosciences, Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.inhibrx.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Inhibrx Biosciences, Inc.於2024年1月8日根據特拉華州法律成立，是Inhibrx, Inc.的直接全資子公司。該公司是一家臨床階段的生物製藥公司，擁有一系列新型候選生物治療藥物，使用其專有的模塊化蛋白質工程平台開發。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/INXB/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INXB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INXB\",,,,,undefined,":{"symbol":"INXB","market":"US","secType":"STK","nameCN":"Inhibrx Biosciences, Inc.","latestPrice":15.86,"timestamp":1717099200000,"preClose":15.86,"halted":8,"volume":0,"delay":0,"floatShares":14240000,"shares":14240000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"07-25 12:27:59 EDT","open":15.86,"high":15.86,"low":15.86,"amount":10976590.3275,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1753473600000},"marketStatusCode":2,"symbolChange":{"newSymbol":"INBX","executeDate":"2024-05-31"},"adr":0,"exchange":"NASDAQ","adjPreClose":15.86,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INXB\",,,,,undefined,":{"symbol":"INXB","floatShares":14240000,"roa":"--","roe":"--","lyrEps":0,"shares":14240000,"dividePrice":0,"high":15.86,"amplitude":0,"preClose":15.86,"low":15.86,"week52Low":15.86,"pbRate":"--","week52High":15.86,"institutionHeld":0,"latestPrice":15.86,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":15.86},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.inhibrx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0102},{"period":"1month","weight":0.0456},{"period":"3month","weight":0.1522},{"period":"6month","weight":0.0435},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Inhibrx Biosciences, Inc.於2024年1月8日根據特拉華州法律成立，是Inhibrx, Inc.的直接全資子公司。該公司是一家臨床階段的生物製藥公司，擁有一系列新型候選生物治療藥物，使用其專有的模塊化蛋白質工程平台開發。","exchange":"NASDAQ","name":"Inhibrx Biosciences, Inc.","nameEN":"Inhibrx Biosciences, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"INXB\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INXB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-31","symbol":"INXB","oldSymbol":"INXB","defaultRemindTime":1717162200000,"newSymbol":"INBX","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1717128000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INXB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INXB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1723608000000}}}